跳转至内容
Merck

1457301

USP

萘普生

United States Pharmacopeia (USP) Reference Standard

别名:

(S)-(+)-2-(6-甲氧基-2-萘基)丙酸

登录查看公司和协议定价


About This Item

线性分子式:
CH3OC10H6CH(CH3)CO2H
CAS号:
分子量:
230.26
Beilstein:
3591068
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

naproxen

製造商/商標名

USP

技術

HPLC: suitable
gas chromatography (GC): suitable

mp

152-154 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O

InChI

1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

InChI 密鑰

CMWTZPSULFXXJA-VIFPVBQESA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Naproxen USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Dexamethasone Compounded Oral Suspension
  • Naproxen
  • Naproxen Compounded Oral Suspension
  • Naproxen Delayed-Release Tablets
  • Naproxen Oral Suspension
  • Naproxen Tablets
  • Terazosin Tablets

生化/生理作用

非选择性环加氧酶(COX-1 和 COX-2)抑制剂。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

訊號詞

Warning

危險分類

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Christopher Derry et al.
The Cochrane database of systematic reviews, (1)(1), CD004234-CD004234 (2009-01-23)
Naproxen, a non-steroidal anti-inflammatory drug, is used to treat various painful conditions including postoperative pain, and is often administered as the sodium salt to improve its solubility. This review updates a 2004 Cochrane review showing that naproxen sodium 550 mg
Marta L Capone et al.
Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)
We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5
Larisa Kovacevic et al.
Pediatric nephrology (Berlin, Germany), 18(8), 826-829 (2003-05-30)
A 17-year-old healthy girl was admitted to our hospital with diffuse abdominal pain and decreased oral intake of about 11 days duration. About a week prior to admission, she had taken naproxen, 250 mg four times a day for 4
Chuthamanee C Suthisisang et al.
Headache, 50(5), 808-818 (2010-03-20)
To assess the efficacy and safety of naproxen sodium in the treatment of acute migraine attacks. Non-steroidal anti-inflammatory drugs including naproxen sodium have been used in treating migraine attack. A number of clinical trials of naproxen sodium in migraine have
Anke Prudic et al.
Molecular pharmaceutics, 11(11), 4189-4198 (2014-10-09)
The incorporation of poorly soluble active pharmaceutical ingredients (APIs) into excipients (e.g., polymers) to formulate an amorphous solid dispersion is a promising strategy to improve the oral bioavailability of the API. The application of copolymer excipients allows access to combinations

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门